Lugano Classification News Today

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib ...

-- Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as...

21.12.2023 - Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase ...

– First Ever Prospective Phase 2 Study to Evaluate CAR T-Cell Therapy as First-Line Therapy Reads Out Three-Year Follow-Up Analysis – – At Median Follow-Up of 40.9 Months, Patients Treated...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...